Tumour biomarker testing: questions to ask your oncologist

A laboratory panel with a long list of genes can look more informative than a focused test. Before comparing offers, ask which decision the oncologist wants the result to support. The practical goal is to connect a suitable test, a usable sample and a clinical interpretation. Buying a report without arranging that interpretation can leave the original treatment question unresolved.

Start with the purpose, not the panel size

Biomarker testing examines features such as genes or proteins that may inform cancer treatment. Some tests look at one marker; others examine several. Testing may find no useful treatment match, and a match does not guarantee benefit. The NCI guide to biomarker testing explains these limits.

Ask the oncologist to complete this sentence: “We are requesting this test now because its result could help us decide…”. Keep the answer with the laboratory order. Then establish what is expected to happen if a relevant finding is present, absent or unclear. A useful discussion explains both why the test has been suggested and how its result will reach the next medical decision.

Tell the team about previous testing before arranging another panel. Provide the complete reports rather than a message saying “genetics was normal”. Ask whether the proposed work repeats an existing analysis, fills a specific gap or answers a different question. Do not decide that a previous test is adequate or inadequate from its commercial name alone.

Confirm the exact test and the quoted service

Request the laboratory name, the test name as it will appear on the report and the material required. Ask the prescribing team whether those details correspond to the intended clinical question. If a coordinator provides several commercial options, have the clinical choice clarified before using turnaround time or price as the deciding factor.

• Does the quote cover sample assessment, the requested analysis and a complete written report?
• Who discusses the result with the patient, and is that consultation included or booked separately?
• What happens if the laboratory cannot complete the requested test?
• Which further work would need new permission and an additional quote?
• Who can resolve a disagreement between the laboratory request and the material supplied?

Write down what has actually been confirmed. “Report expected in ten days”, for example, should be clarified as a laboratory estimate with a defined starting point, not turned into a promised treatment date. Keep travel arrangements separate until the treating team confirms what the result is expected to change.

Coordinate the sample without arranging procedures yourself

Give the team the location of stored tissue, its specimen number, collection date and the treatment history associated with it. The receiving laboratory should specify what it requires and confirm whether the material can be used. If slides or blocks must move between institutions, follow the pathology material transfer checklist rather than treating the shipment as ordinary paperwork.

If a blood-based test is offered instead of tissue testing, ask the oncologist what that test can answer in your case and what would happen after an uninformative result. Do not assume the options are interchangeable. Likewise, a difficulty obtaining stored material is not a reason to organise a fresh biopsy independently. The clinical team must weigh whether another procedure is appropriate.

Separate tumour testing from inherited cancer risk

Tumour testing and testing for inherited cancer susceptibility serve different purposes. A tumour result may raise an inherited-risk question, but it does not replace the appropriate assessment. The NCI inherited cancer risk guide explains why separate testing and a genetics consultation may be needed.

Before consent, ask whether the test could report findings beyond the immediate treatment question and who would explain them. If a possible inherited finding appears, request a specific next step rather than drawing conclusions about relatives from the tumour report. Ask which institution stores the result and how you can obtain the complete document for an independent consultation.

Arrange a result discussion with a clear structure

Take the full report to the appointment, including methods and limitations. A variant of uncertain significance is not an established treatment target; NCI notes that uncertain findings are not used to make treatment decisions. Ask the clinician to explain which part of the report is relevant to today’s question.

1. The finding: ask the doctor to identify the exact result being discussed.
2. The meaning: request a plain-language explanation of its relevance to your diagnosis.
3. The evidence: ask what supports the proposed interpretation and what uncertainty remains.
4. The next action: record whether the recommendation is a current option, a further assessment or a question for a research team.
5. The owner: identify who will carry out that next step and contact you.

For a possible treatment match, the discussion of immunotherapy and targeted therapy can help you prepare practical questions. A medicine name in a report is not confirmation of a prescription, local availability or acceptance into a trial. Have those matters checked separately by the responsible institution.

Protect the existing care plan

Ask the treating oncologist how the test fits around current care and whether a pending result changes any agreed timing. Do not stop or delay treatment on the basis of this article or a laboratory advertisement. If another specialist will review the result, include the original clinical question in the second-opinion request so that the conversation stays focused.

Before arranging cancer care in Turkey, seek a written explanation connecting the report to the proposed next step. The useful outcome is not the largest panel or the longest list of possible medicines. It is a result that the medical team can interpret within your diagnosis, existing care and practical circumstances.

Sources

• NCI: Biomarker Testing for Cancer Treatment
• NCI: Genetic Testing for Inherited Cancer Risk